PMID- 29143362
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20191217
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 45
IP  - 5
DP  - 2018 May
TI  - MicroRNA-26a inhibits proliferation and tumorigenesis via targeting CKS2 in 
      laryngeal squamous cell carcinoma.
PG  - 444-451
LID - 10.1111/1440-1681.12890 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is one of the most common head and neck 
      cancers, with high mortality and incidence. MicroRNA-26a (miR-26a) is involved in 
      the development and progression of several tumours. However, the roles of miR-26a 
      and its target CKS2 in LSCC progression are not yet clear. The mRNA and protein 
      expression was determined using RT-PCR and Western blotting assay, respectively. 
      Cell proliferation was detected using a Cell Counting kit-8 assay (CCK-8). 
      Transwell assay was used to evaluate cell migration and invasion. Dual-luciferase 
      reporter assay was applied to determine the relationship between miR-26a and 
      CKS2. In addition, a tumour xenograft model in nude mice was established to 
      further determine the effects of miR-26a on tumourigenesis. In this study, we 
      found that miR-26a level was down-regulated in LSCC tissues and cell lines, while 
      CKS2 expression was increased. Cell proliferation, migration, invasion and the 
      expression of MMP2 and MMP9 was suppressed by miR-26a overexpression, but 
      enhanced by inhibition of miR-26a. Dual-luciferase reporter assay demonstrated 
      that CKS2 is a direct target of miR-26a in AMC-HN-8 cells. Overexpression of 
      miR-26a caused a significant reduction in CKS2 expression, and reinforced 
      expression of CKS2 abolished the tumour-suppressive function of miR-26a. 
      Moreover, miR-26a inhibited tumour growth in vivo. Taken together, miR-26a 
      inhibited proliferation and tumourigenesis of LSCC via targeting CKS2 in vitro 
      and in vivo.
CI  - (c) 2017 John Wiley & Sons Australia, Ltd.
FAU - Wu, Zhiyan
AU  - Wu Z
AD  - Department of Otolaryngology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
FAU - Lu, Baocai
AU  - Lu B
AD  - Department of Otolaryngology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
FAU - Li, Xiao
AU  - Li X
AD  - Department of Otolaryngology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
FAU - Miao, Wenjie
AU  - Miao W
AD  - Department of Otolaryngology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
FAU - Li, Jin
AU  - Li J
AD  - Department of Otolaryngology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
FAU - Shi, Yongjuan
AU  - Shi Y
AD  - Department of Anesthesiology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
FAU - Yu, Wenfa
AU  - Yu W
AUID- ORCID: 0000-0003-0269-3085
AD  - Department of Otolaryngology, The First Affiliated Hospital of Xinxiang Medical 
      College, Xinxiang, Henan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180108
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Carrier Proteins)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (MIRN26A microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.11.22 (CDC2-CDC28 Kinases)
RN  - EC 2.7.11.22 (CKS2 protein, human)
MH  - Animals
MH  - CDC2-CDC28 Kinases/*genetics
MH  - Carcinogenesis/*genetics
MH  - Carcinoma, Squamous Cell/genetics/*pathology
MH  - Carrier Proteins/*genetics
MH  - Cell Cycle Proteins/*genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Cell Transformation, Neoplastic
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Neoplasm Invasiveness
OTO - NOTNLM
OT  - cyclin-dependent kinases regulatory subunit 2
OT  - laryngeal squamous cell carcinoma
OT  - microRNA-26a
OT  - migration
OT  - proliferation
EDAT- 2017/11/17 06:00
MHDA- 2019/08/17 06:00
CRDT- 2017/11/17 06:00
PHST- 2017/08/23 00:00 [received]
PHST- 2017/10/10 00:00 [revised]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/11/17 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2017/11/17 06:00 [entrez]
AID - 10.1111/1440-1681.12890 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2018 May;45(5):444-451. doi: 10.1111/1440-1681.12890. 
      Epub 2018 Jan 8.